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Abstract 
Aims  
Since the inception of the NHS, an ever-present challenge has been to improve integration of care 
within the health care system and with social care. Many people have complex and ongoing care 
needs and require support from multiple agencies and various professionals. But care is often 
fragmented and uncoordinated, with no one agency taking overall responsibility, so it is often left to 
ŝŶĚŝǀŝĚƵĂůƐĂŶĚƚŚĞŝƌĨĂŵŝůŝĞƐƚŽŶĞŐŽƚŝĂƚĞƚŚĞƐǇƐƚĞŵĂƐďĞƐƚƚŚĞǇĐĂŶ ?^ŽƵƚŚ^ŽŵĞƌƐĞƚ ?Ɛ^ǇŵƉŚŽŶǇ
is designed to establish greater collaboration between primary, community, acute and social care, 
particularly for people with complex conditions.  
 
Methods 
We examine patterns of health and social care utilisation and costs for the local population to 
identify which groups of people would most benefit from better integrated care. We analyse data to 
identify groups of people according to the frequency of occurrence of underlying conditions; the 
cost of care; and utilisation of services across diverse settings. The empirical identification strategy is 
supplemented by local intelligence gained through workshops with health and social care 
professionals about the appropriateness of existing patterns of provision. We employ two-part 
regression models to explain variability in individual health and social costs, in total and in each 
setting. 
 
Data 
The Symphony Project has an anonymised individual-level dataset, spanning primary, community, 
acute, mental health and social care. This includes activity, costs, clinical conditions, age, sex and 
ǁĂƌĚ ŽĨ ƌĞƐŝĚĞŶĐĞ ĨŽƌ ƚŚĞ ĞŶƚŝƌĞ ƉŽƉƵůĂƚŝŽŶ ŽĨ  ? ? ? ? ? ? ? ƉĞŽƉůĞ ŝŶ  ? ? ? ? ? ĂĐŚ ƉĞƌƐŽŶ ?Ɛ ŵŽƌďŝĚŝƚǇ
ƉƌŽĨŝůĞŝƐĚĞƐĐƌŝďĞĚƵƐŝŶŐƚŚĞhŶŝƚĞĚ,ĞĂůƚŚ ?ƐƉŝƐŽĚĞdƌĞĂƚŵĞŶƚ'ƌŽƵƉƐ ?d' ? ?ǁŚŝĐŚďƵŝůĚƵƉŽŶ/
and Read codes. 
 
Results 
We identify the frequency of conditions and co-morbidity profile of the entire population and, for 
the most frequent conditions, we assess utilization and costs of care across health and social care 
settings. For example, for those with asthma and diabetes, hospital costs account for the largest 
proportion of costs; in contrast, costs for those with dementia occur mostly in social care, mental 
health care and community care settings. For the population as a whole, we find that costs of health 
and social care are driven more by an individuĂů ?ƐŵŽƌďŝĚŝƚǇƉƌŽĨŝůĞƚŚĂŶďǇƚŚĞŝƌĂŐĞ ?
 
Data for those with the most frequent conditions were reviewed by local health and social care 
professionals and managers. It was decided to undertake more detailed analyses for those with 
diabetes or dementia. 5,676 people are recorded as having diabetes in South Somerset, with 
hypertension being the most common comorbidity. For those with a sole diagnosis of diabetes, costs 
are around £1,000 on average but as people are recorded as having more diagnoses, average costs 
increase progressively. Costs are also higher for older people and women. 
 
People with dementia account for only 0.92% of the South Somerset population, but the average 
annual cost for the 1,062 people with dementia is around £12,000. A high proportion of these costs 
are related to the provision of mental health, social and continuing care. Costs are higher the more 
co-morbidities a person has, and for people from more deprived areas. Age and gender do not 
explain variation in costs for people with dementia. 
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Conclusions 
This work forms a basis for identifying groups that would most benefit from improved integrated 
care, which might be facilitated by integrated financial arrangements and better pathway 
management. The more co-morbidities that a person has, the more likely they are to require care 
across diverse settings, and the higher their costs. Our analysis identifies those groups of the 
population which are the highest users of services by activity and cost and provides baseline 
information to allow budgetary arrangements to be developed for these targeted groups. 
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1. Introduction 
Since the inception of the NHS, an ever-present challenge has been to improve integration of care 
within the health care system and with social care. Many people have complex and ongoing care 
needs and require support from multiple agencies and various professionals (Lehnert et al., 2011). 
But care is often fragmented and uncoordinated, with no one agency taking overall responsibility, so 
it is often left to individuals and their families to negotiate the system as best they can.  
 
Traditionally, in England, health and social care funds have been channelled to institutions not 
individuals. Institutionally-based funding fails to recognise that many people, particularly those with 
combinations of conditions, move across institutions, receiving care in multiple settings. But this 
creates problems. Patients find it difficult to negotiate their way through the health and care system. 
Care providers have had little financial incentive and have lacked financial mechanisms to allow 
funding to follow patients as they move from one setting to another. It has been recognised that 
financial arrangements need to be revised so as to support rather than inhibit organisations to work 
collaboratively around the needs of patients (Department of Health, 2012). 
 
^ŽƵƚŚ^ŽŵĞƌƐĞƚ ?Ɛ^ǇŵƉŚŽŶǇWƌŽũĞĐƚŝƐĚĞƐŝŐŶĞĚƚŽĞƐƚĂďůŝƐŚŐƌĞĂƚĞƌĐŽůůĂďŽƌĂƚŝŽŶďĞƚǁĞĞŶƉƌŝŵĂƌǇ ?
community, mental health, acute and social care, particularly for people with complex conditions. 
The Project is based on the principle of collaborative care, centred around the needs of individual 
patients. This means that all of the different organisations involved in delivering services will need to 
work together to deliver a tailored package of care. Collaborative working is to be incentivised by a 
shared outcomes framework. There will be joint responsibility for all organisations to deliver the 
ŽƵƚĐŽŵĞƐ ?ĂŶĚǁŝƚŚůŝŶŬĞĚĨŝŶĂŶĐŝĂůƐƚƌƵĐƚƵƌĞƐƵŶĚĞƌĂŶ ‘ĂůůŝĂŶĐĞĐŽŶƚƌĂĐƚ ? ? 
 
To support this ambition it is necessary to understand what drives health and social care costs. This 
will enable stratification into groups in order to inform the appropriate targeting of the programme 
toward those patient groups which are the highest users of services, who can be identified both by 
activity and cost (Kadam et al., 2013).  Budgetary arrangements can then be developed for these 
targeted groups. 
 
To support these ends, health and social care data have been collated from multiple sources for the 
entire population within the South Somerset GP Federation.  The Federation covers 17 practices 
around Yeovil District Hospital NHS Foundation Trust. In this report we analyse these data in order to 
identify those groups of people for which collaborative care might be most beneficial.  
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2. The Symphony Dataset 
The Symphony Project has built a large dataset which links acute, primary care, community, mental 
health and social care data for each individual in the South Somerset population. The data are 
derived from various primary sources all of which cover twelve months from April 2012 to March 
2013. The dataset contains anonymised individual-level data about what care has been received and 
at what cost across all organisations.  The dataset has three key features: 
 
1. Anonymised data are available for each individual in the population about their utilisation 
of health and social care. Utilisation data for each individual are linked across eight broad 
settings of care:  
a. PC: primary care episodes and prescribing 
b. IP: acute inpatient & daycase 
c. OP: acute outpatient 
d. AE: acute accident & emergency 
e. MH: mental health 
f. CM: community care 
g. SC: social care.  
h. CC: continuing care 
2. Costs have been calculated for each individual according to the type of care they have 
received in each setting. These calculations generally reflect the costs to the commissioner 
of procuring care of a particular type.  
3. Demographic characteristics are available for each individual, including age, gender, socio-
economic measures, and indicators of morbidity.  
 
Describing multi-morbidity 
ĂĐŚŝŶĚŝǀŝĚƵĂů ?ƐŵŽƌďŝĚŝƚǇƉƌŽĨŝůĞ ŝƐĐŽŶƐƚƌƵĐƚĞĚƵƐŝŶŐhŶŝƚĞĚ,ĞĂůƚŚ ?ƐZ/^ƚŽŽů ?Z/^ ŝƐĂƉĂƚŝĞŶƚ-
centric predictive modelling tool developed by United Health UK to assess the risk of patients having 
unplanned hospital admissions within a 12 month period. The tool utilises diagnostic information in 
patient medical records, described using ICD10 and Read codes. This diagnostic information is 
summarised into 586 Episode Treatment Groups (ETGs) which are grouped under 22 Major Practice 
Categories. We designated 49 of these 586 ETGs as indicative of chronic conditions, and these 49 
conditions form of the basis for describing the morbidity profile of each individual in the population. 
Individuals can, of course, have multiple chronic conditions.  
http://www.unitedhealthuk.co.uk/OurTechnology/HealthNumericsRISC.aspx.  
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3. Analytical approach 
The Symphony Project wanted to target collaborative care arrangements initially at a subset of the 
population that would be expected to benefit most. The analytical objective is to identify which 
people might comprise this initial group and to assess what size of commissioning budget should be 
assigned to cover their health and social care requirements. 
 
We have adopted four criteria to identify groups most amenable to an integrated care approach, 
these being:  
1. high frequency of occurrence;  
2. utilisation of services across diverse settings;  
3. high cost of care;  
4. local consensus that changes to the care pathway are feasible.   
The rationale for these criteria and the analytical approach are set out in the box below. 
 
Basis Rationale Analytical approach 
Frequency of 
occurrence 
In developing a budget, there needs to be 
a reasonably large number of people to 
ĨŽƌŵƚŚĞ “ƌŝƐŬƉŽŽů ? ? 
Assess how many people have particular 
chronic conditions (ETG) and 
combinations of conditions. 
Utilisation of 
services across 
settings 
People who require services across diverse 
settings are most likely to benefit from 
collaborative care requirements 
Summarise the number and type of 
settings in which patients receive care by 
chronic condition/s. 
Costs of care Potential savings are likely to be greater 
the higher are the costs of care. 
Summarise total costs and setting-
specific costs by chronic condition/s.  
Potential for change Changes require local ownership and 
action 
Workshops with the local health and 
social care community 
 
Frequency of occurrence 
In developing a budget that covers health and social care requirements, our starting point was that: 
1.  ƌĞĂƐŽŶĂďůǇ ůĂƌŐĞ ŶƵŵďĞƌ ŽĨ ƉĞŽƉůĞ ƚŽ ĨŽƌŵ ƚŚĞ  “ƌŝƐŬ ƉŽŽů ? ? /Ŷ ƚŚĞ ĞǆƉĞĐƚĂƚŝŽŶ ƚŚĂƚ Ă
large proportion of costs incurred by any particular individual is difficult to predict, there 
needs to a sufficiently large risk pool so that those with high costs are offset by those with 
low costs. 
2. Moreover, the arrangements should be targeted at people with multiple conditions as 
these are more likely to require collaborative care arrangements. We employed the 49 
chronic conditions (ETG classifications) to describe multi-morbidity and to develop 
meaningful groups of patients.  
 
Utilisation of services across diverse settings 
We believe that people who require services across diverse settings are most likely to benefit from 
collaborative care requirements. The data allow us to examine the overall pattern of expenditure in 
South Somerset across settings for people with each chronic condition. We constructed eight types 
of setting: 
x PC: primary care episodes and prescribing 
x IP: acute inpatient & daycase 
x OP: acute outpatient 
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x AE: acute accident & emergency 
x MH: mental health 
x CM: community care 
x SC: social care.  
x CC: continuing care 
WĂƚŝĞŶƚ ‘ƵƚŝůŝƐĂƚŝŽŶ ?ǁĂƐĚĞƐĐƌŝďĞĚŝŶĞĂĐŚƐĞƚƚŝŶŐŽĨĐĂƌĞĂƐĨŽůůŽǁƐ P 
 ? In Primary ĂƌĞ ? ƚŚĞ ƚĞƌŵ  ‘ĞƉŝƐŽĚĞƐ ? ƌĞĨĞƌƐ ƚŽ Ă ǁŝĚĞƌ ŵĞĂƐƵƌĞ ƚŚĂŶ ŵĞƌĞůǇ  ‘'W
ĐŽŶƐƵůƚĂƚŝŽŶƐ ? ? dŚƌŽƵŐŚ ƚŚĞ Z/^ ƐǇƐƚĞŵ ǁĞ ǁĞƌĞ ĂďůĞ ƚŽ ŝĚĞŶƚŝĨǇ ĞĂĐŚ ƚŝŵĞ  ?ĞƉŝƐŽĚĞ ? Ă
patient interacted with their GP Practice, either through a physical visit (either to a GP or 
other health professional) or an event that caused a Read code to be recorded against the 
ƉĂƚŝĞŶƚ ?Ɛ ƌĞĐŽƌĚ  ‘ŝŶ ĂďƐĞŶƚŝĂ ? ? WƌŝŵĂƌǇ ĂƌĞ ĐŽƐƚƐ  ?ĂƐ ŝĚĞŶƚŝĨŝĞĚ ĐŽůůĞĐƚŝǀĞůǇ ďĞƚǁĞĞŶ ƚŚĞ
South Somerset GP Federation and the Local Area Team of NHS England) were allocated to 
ƉĂƚŝĞŶƚƐŽŶƚŚĞďĂƐŝƐŽĨĂĐĂůĐƵůĂƚĞĚ ‘ƵŶŝƚĐŽƐƚƉĞƌƉƌŝŵĂƌǇĐĂƌĞĞƉŝƐŽĚĞ ? ? 
 ? Prescribing utilisation was calculated with reference to utilisation data from the RISC tool 
and prescribing budgets managed by Somerset Clinical Commissioning Group. 
 ? Acute and community care utilisation was based on activity and cost information sourced 
through the NHS Secondary Users Service (SUS) including the number, type and length of 
hospital episodes. 
 ? DĞŶƚĂů ŚĞĂůƚŚ ƵƚŝůŝƐĂƚŝŽŶ ǁĂƐ ďĂƐĞĚ ŽŶ  ‘ŵĞŶƚĂů ŚĞĂůƚŚ ĐůƵƐƚĞƌ ĐŽƐƚƐ ? ? ĂƐ ĐĂůĐƵůĂƚĞĚ ĂŶĚ
supplied by Somerset Partnership NHS Foundation Trust, the local provider of mental 
health services. 
 ? Social Care utilisation was based on activity and cost information provided directly by 
Somerset County Council, including utilisation of homecare, residential placements, day 
care, professional services, direct support and provision of equipment. Note that utilisation 
of social care is identified if any one of seven types of social care support are utilised by a 
particular individual. 
 ? Continuing Care was based directly on cost information provided by the local Continuing 
Healthcare team hosted by South West Commissioning Support and supporting Somerset 
Clinical Commissioning Group. 
 
Analysing variation in costs 
We analyse why costs vary from one person to another by applying multivariate regression models 
ƚŽĂŶĂůǇƐĞĞĂĐŚƉĞƌƐŽŶ ?ƐƚŽƚĂůĐŽƐƚƐĂŶĚĐŽƐƚƐŝŶĐƵƌƌĞĚŝŶĞĂĐŚŽĨƚŚĞĞŝŐŚƚƐĞƚƚŝŶŐƐ ?ƐŝƐƚǇƉŝĐĂůŝŶ
modelling health costs, we use a logarithmic transformation to reduce skewness and make the 
distribution more symmetric and closer to normality. A high proportion of people in inpatient, 
outpatient, A&E, mental health, community care, social care, and continuing care incur no costs. To 
analyse costs in such settings, we employ two-part models (Charlton et al., 2013, Brilleman et al., 
2012, Duan et al., 1983) which allow us to account for the large number of zeros found in the data. 
The two parts are assumed to be independent and can be estimated separately. The first part, 
estimated by a logistic regression, models the probability of incurring any expenditure and the 
second part models the amount of expenditure only for those with positive costs. The conditional 
mean independence assumption is then given by: 
Eiiii XXyyE  ! ),0|(ln  
where yi are costs for individual i, Xi is a vector of explanatory variables and E  indicates the 
parameter estimates. Primary care costs and total costs exhibit a very small proportion of zeros and 
are estimated by a simple log-linear regression. 
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We consider two sets of explanatory variables: 
x A limited set of variables commonly used in analyses of this kind. These variables are age, 
gender, social deprivation, the number of chronic conditions, and whether patients died 
during the year or moved elsewhere. 
x The full set of variables which, in addition to those listed above, includes co-morbidity 
variables indicating whether or not a person has a particular condition, namely Dementia, 
Mental health (excluding dementia), Cancer, Cardio-vascular disease, Stroke, Obesity, 
Respiratory problems, Gastric problems, Trauma/burns/fractures, Arthritis, or Renal 
problems. 
 
We assess explanatory power by looking at the R
2
 statistic. This summarises the overall ability of the 
variables included in the model to explain variation in observed costs. The following points are worth 
bearing in mind: 
 
x Individual health and social care costs are difficult to predict, so we would not expect 
explanatory power to be particularly high. R
2
 statistics of around 15-20% would be deemed 
satisfactory in most studies of this kind (Nagl et al., 2012). 
x The explanatory power of the limited model will be lower than the full model, simply 
because fewer variables are included. By comparing the R
2
 statistic from both models we 
can assess whether it is worth including the additional information required to specify the 
full model. 
x Explanatory power will vary across settings, because costs vary across settings and the 
characteristics that explain costs in one setting may be different from those that explain 
costs in another.  
 
Potential for change  
We presented details of multi-morbidity profiles for those with particular conditions at a workshop 
with local health and social care professionals and managers. Clinical/practitioner and managerial 
representation was present for all of the major organisations involved (it is anticipated that there 
will be involvement and impact on many smaller organisations such as local charities, which will not 
be part of the alliance contract).  
 
There were acknowledged to be conflicting pressures on the choice of group to which the Symphony 
budgetary arrangements should apply initially. Discussion covered whether specific conditions 
should be used or multi-morbidity. Multi-morbidity, as measured by number of conditions alone, 
would potentially benefit a larger group but would represent difficulties when patients presented to 
an organisation  W ŚŽǁǁŽƵůĚƐƚĂĨĨƌĞĐŽŐŶŝƐĞƚŚĞ ‘^ǇŵƉŚŽŶǇWĂƚŝĞŶƚ ? ?ůĂƌŐĞƌĐŽŚŽƌƚǁŽƵůĚŵĂŬĞŝƚ
easier for organisations to make coherent changes to their working practices so that staff would not 
be asked to work in one way with one group of patients and in another way with the remainder. A 
ůĂƌŐĞƌƉĂƚŝĞŶƚŐƌŽƵƉǁŽƵůĚĂůƐŽƌĞƐƵůƚŝŶŐƌĞĂƚĞƌ “ƌŝƐŬƉŽŽůŝŶŐ ?ĂƐĚĞƐĐƌŝďĞĚĂďŽǀĞ ?,ŽǁĞǀĞƌĂůĂƌŐĞƌ
ŐƌŽƵƉ ǁŽƵůĚ ƌĞƉƌĞƐĞŶƚ Ă ďŝŐŐĞƌ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ĞĂĐŚ ŽƌŐĂŶŝƐĂƚŝŽŶ ?Ɛ ƚŽƚĂů ďƵĚŐĞƚ ĂŶĚ ƚŚĞƌĞĨŽƌĞ Ă
greater risk to the organisation if the proposed interventions failed to deliver the expected benefits. 
A larger group would also make it harder to make a significant difference to the outcomes of the 
group in a short space of time, and would take longer to mobilise.   
 
The decision was then taken to focus further analytical effort on those with a diagnosis of diabetes 
and of dementia. This was thought to provide an acceptably large patient group with an expected 
resource budget that was acceptable to all parties.  
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4. Descriptive statistics 
The Symphony dataset contains information about 114,874 people. Information about each person 
is available on the following: 
x Utilisation and costs of care across settings 
x Socio-demographic characteristics 
x The chronic conditions of each individual used to describe their multi-morbidity profile.  
Utilisation and costs of health and social care 
Table 1 summarises utilisation and costs of care according to the type of health and social care 
utilised for the South Somerset population as a whole. On average, people had 4.79 primary care 
episodes over the course of the year, received 3.49 unique prescriptions, and had 0.32 inpatient 
admissions. While some people did not use any service of a particular type, there are some very high 
users. Some of the utilisation variables are recorded in terms of whether or not people received the 
care in question. So, for instance, 1.51% of the population received mental health care, 0.69% 
received homecare and 2.64% received professional support. 
 
Table 1 Summary statistics - utilisation and average costs per person (£) 
 
Variable 
Utilisation  Costs 
Mean SD Max %  Mean SD Max 
Prescriptions 3.491 5.025 65 66.08  128 185 2388 
GP  4.787 6.308 113 78.92  69 90 1618 
Acute 
Inpatient 0.320 2.721 163 14.90  380 1561 76120 
Outpatient 1.040 2.445 66 30.19  106 242 5863 
A&E 0.224 0.694 24 13.77  20 67 2296 
Community 
Inpatient 0.004 0.075 3 0.36  34 783 78210 
Outpatient 0.006 0.110 6 0.33  1 12 606 
A&E 0.014 0.192 25 0.99  1 11 1398 
Mental health 0.023 0.339 33 1.51  70 1620 138927 
Social care 
Homecare 0.010 0.101 1 0.69  23 451 31931 
Placement 0.011 0.159 9 0.77  73 1467 315950 
Day care 0.002 0.045 1 0.20  8 249 43680 
Direct pay 0.002 0.062 4 0.19  13 445 44842 
Equipment 0.009 0.094 1 0.87  2 36 4155 
Other services 0.000 0.021 1 0.04  1 55 2684 
Prof. support 0.026 0.160 1 2.64  30 183 1140 
Continuing care 
CHC Nursing home 0.003 0.058 1 0.34  14 267 11314 
Funding 0.004 0.088 5 0.27  53 1908 215152 
Total      1026 4112 460103 
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The average cost of care amounted to £1026 but there is wide variation in costs, with some people 
incurring high costs  W the care for one person amounted to £460,103. The data permit analysis of 
costs according to the care setting. For example, the average cost of inpatient care amounted to 
£380, but many people incurred zero inpatient costs while the cost for one person amounted to 
£76,120. The average cost of social care placements amounted to £73, but reached £315,950 for one 
individual. 
Demographic characteristics 
Table 2 summarises the characteristics of the population. The average age of the population is 43 
years and 49% are male. During the course of the year, 0.9% of the population died and 2.7% moved 
out of the area. As in other studies (Charlton et al., 2013, Brilleman et al., 2012, Kadam et al., 2013), 
we account for socio-economic circumstances by using an Index of Multiple Deprivation, which 
ŵĞĂƐƵƌĞƐ ƚŚĞ ĚĞƉƌŝǀĂƚŝŽŶ ŽĨ ƚŚĞ ĞĂĐŚ ƉĞƌƐŽŶ ?Ɛ ƌĞƐŝĚĞŶƚŝĂů Ăƌea (electoral ward) 
(http://www.ons.gov.uk/ons/index.html). 
Conditions are defined in the data set according to the Episode Treatment Group (ETG) 
classifications employed by the United Health RISC tool. Taking the population as a whole, the 
average person has 4.03 conditions (i.e. ETGs), of which 0.94 are chronic conditions. 
Table 2 Summary statistics - background variables 
 
Morbidity and multi-morbidity  
Over and above socio-demographic characteristics, it is most likely that costs will be driven by the 
conditions that people have (Lehnert et al., 2011). While many people do not have any of the ETGs 
that we have defined as chronic conditions, some have multiple chronic conditions.  
Table 3 presents information on the prevalence of the 49 chronic conditions among the South 
Somerset population. Almost 16% of the population has a diagnosis of hypertension, 11% have 
asthma. Many of the conditions are experienced by less than 1% of the population.  
We can also examine the prevalence of combinations of chronic conditions. There are 7,605 unique 
combinations of chronic conditions among the South Somerset population. It is impractical to report 
each combination, but we can examine the number of conditions that people with particular 
conditions have. For example, 72% of those with hypertension also have another chronic condition.  
In Figure 1 to Figure 3, for each of the chronic condition listed in Table 3, we summarise the 
percentages of those with that condition who (i) have that condition alone; (ii) have another 
condition as well; (iii) have two other conditions; and (iv) have three or more other conditions. The 
conditions are ordered across all three graphs from the most frequent in the population 
(hypertension) to the least frequent (hepatitis). So we can see, for instance, that almost 50% of 
those with asthma have no other condition. In contrast, about 10% of those who have suffered a 
stroke or who have COPD have only this condition, while more than 50% of these people are 
recorded as having more than three conditions.  
Variable % Mean Std Dev Min Max 
Male 48.93 
    
Died 0.90 
    
Moved elsewhere 2.66 
    
Age  42.648 24.359 0 105 
Index of Multiple Deprivation  14.75 8.32 2.31 73.73 
Number of conditions  4.027 4.243 0 70 
Number of chronic conditions  0.937 1.306 0 13 
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Table 3 Prevalence and costs by chronic condition (ETG) 
Chronic Condition 
Prevalence  Costs 
N % 
% with >1 
conditions 
 Mean Std Min Max 
None 58,362 50.81 NA  293 2,350 9 460,103 
Hypertension 17,777 15.48 72.44  2,546 5,950 0 237,924 
Asthma 12,769 11.12 51.47  1,337 4,457 0 218,562 
Anxiety 7,962 6.93 67.14  2,067 6,283 0 237,924 
Cancer 5,932 5.16 81.98  3,195 5,887 0 117,582 
Irritable Bowel Syndrome 5,688 4.95 67.33  1,438 3,770 0 124,177 
Diabetes 5,676 4.94 85.62  3,036 7,153 0 237,924 
Skin infections 5,086 4.43 61.80  2,422 6,739 0 218,562 
Coronary Artery Disease 4,695 4.09 85.18  3,911 7,145 0 136,382 
Hypothyroidism 4,275 3.72 77.31  2,353 6,474 0 237,924 
Skin trauma 3,611 3.14 63.17  2,679 8,228 14 237,924 
Stroke 2,665 2.32 90.28  5,231 10,233 0 237,924 
Tendinitis 2,578 2.24 71.33  1,970 5,729 14 177,796 
Gastroenterology signs & 
symptoms 
2,144 1.87 66.46  2,756 5,328 14 92,328 
Chronic Obstructive 
Pulmonary Disease 
1,989 1.73 89.84  3,802 6,503 0 97,235 
Breast disorders 1,951 1.70 86.78  2,270 4,115 0 40,040 
Fractures 1,546 1.35 67.27  4,663 8,459 14 122,643 
Epilepsy 1,470 1.28 64.42  3,511 11,271 0 237,924 
Gastritis 1,344 1.17 77.01  2,357 4,618 14 54,558 
Hernias 1,336 1.16 79.04  3,293 5,480 14 81,153 
Mental health 1,294 1.13 81.30  5,519 12,933 0 237,924 
Gynecological infections 1,157 1.01 63.09  2,221 4,715 14 100,826 
Hemorrhoids 1,152 1.00 72.40  2,106 4,209 14 57,457 
Appendicitis 1,120 0.97 86.43  3,594 5,962 14 97,768 
Pneumonias 1,110 0.97 73.24  5,086 11,578 14 218,562 
Heart Failure 1,106 0.96 93.49  5,742 7,922 0 77,059 
Dementia 1,062 0.92 87.76  12,314 19,654 0 237,924 
Cataract 1,023 0.89 91.89  3,761 5,827 14 69,207 
Adult Rheumatoid Arthritis 840 0.73 82.50  3,658 5,446 0 43,105 
Glaukoma 810 0.71 80.99  2,430 5,628 14 99,128 
Open wound 708 0.62 81.36  5,104 8,136 14 78,675 
Chronic kidney Disease/Renal 
failure 
640 0.56 96.25  8,694 9,432 0 49,932 
Late effects complications 637 0.55 79.43  6,141 8,254 14 77,629 
Acute bronchitis 630 0.55 62.22  1,954 4,208 14 41,730 
Cirrhosis 518 0.45 81.66  2,334 4,880 0 53,732 
Obesity 487 0.42 85.83  4,038 6,947 14 117,582 
Environmental trauma 445 0.39 66.52  2,614 7,783 14 109,899 
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Nutritional Deficiency 366 0.32 87.16  4,766 7,933 51 55,449 
Poisionings & effects of  drugs 310 0.27 74.19  5,686 12,829 43 124,177 
Macular degeneration 305 0.27 95.08  4,414 6,880 80 69,207 
Burns 285 0.25 55.44  2,651 16,461 0 237,924 
Incontinence 246 0.21 76.83  2,607 5,093 0 61,679 
Alcohol dependence 177 0.15 94.35  6,534 10,213 108 73,018 
Kidney stones 152 0.13 75.66  3,328 5,121 14 39,890 
Eating disorders 126 0.11 59.52  2,838 11,406 0 97,235 
Pancreatitis 115 0.10 86.09  4,564 5,318 0 30,652 
Ulcer 105 0.09 90.48  7,793 9,823 139 55,449 
Diabetic Retinopathy 95 0.08 93.68  5,425 7,304 756 40,851 
Occupational Pulmonary 
disease 
45 0.04 95.56  14,142 13,422 51 54,121 
Hepatitis 31 0.03 77.42  3,855 5,428 65 19,767 
 
 
 
 
Figure 1 Patients with multiple chronic conditions (ETGs), by condition (1 of 3) 
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Figure 2 Patients with multiple chronic conditions (ETGs), by condition (2 of 3) 
 
 
 
Figure 3 Patients with multiple chronic conditions (ETGs), by condition (3 of 3) 
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5. The costs of health and social care 
For the population as a whole, Figure 4 shows how average costs vary according to the number of 
chronic conditions that are recorded. The average cost by the number of conditions is reported 
below each column. 
 
 
Figure 4 Average cost, full sample 
 
There are a few things of note: 
x Some people incur costs even though they have no chronic conditions: the average cost for 
such people amounts to £293. Some people in this group will have conditions other than 
the 49 chronic conditions that are the focus of the analysis; many will have incurred no 
costs at all. 
x As might be expected, average costs increase the more conditions that people have. This is 
indicated by the increase in the height of the columns from left to right. 
x More surprising, the marginal increase in average costs initially rises the more conditions 
are recorded. So, for instance, the average cost for the 14,056 people with two conditions 
is £860 more than the average cost for the 29,447 people with one condition; the 
difference between those with 3 and those with 2 conditions amounts to £1071; the 
difference between those with 4 and 3 conditions amounts to around £1,820. Beyond this, 
marginal cost increases become smaller. 
Total costs by condition and setting 
Information about costs across settings is summarised in Figure 5 to Figure 7 for each chronic 
condition (ETG), ordered by total expenditure (note that the scale varies for each graph). This shows 
that the total costs are highest for those people recorded as having hypertension, with the total cost 
amounting to almost £45m for the 17,777 people recorded as having this condition. But note that 
0 1 2 3 4 5 6 7+
Cost/patient £293 £795 £1,655 £2,726 £4,549 £5,841 £7,325 £11,233
N=58,362
N=29,447
N=14,056
N=6,972
N=3,198
N=1,564
N=758
N=517
£0
£2,000
£4,000
£6,000
£8,000
£10,000
£12,000
A
v
e
ra
g
e
 c
o
st
 p
e
r 
p
a
ti
e
n
t
Average cost per patient by number of ETGs
12  CHE Research Paper 96 
these costs are for those people recorded as having hypertension  W and all the other conditions that 
these people suffer. The total cost is not for treating hypertension alone. 
 
The graphs also show the breakdown in total costs according to each setting. Acute inpatient and 
day ĐĂƐĞĐŽƐƚƐ  ?ůĂďĞůůĞĚ “ŝƉ ? ?ŝŶǀĂƌŝĂďůǇĂĐĐŽƵŶƚĨŽƌƚŚĞůĂƌŐĞƐƚƉƌŽƉŽƌƚŝŽŶďƵƚĨŽƌŵĂŶǇĐŽŶĚŝƚŝŽŶƐ
ƐŽĐŝĂůĐĂƌĞĐŽƐƚƐ ?ůĂďĞůůĞĚ “ƐĐ ? ?ĂŶĚƉƌŝŵĂƌǇĐĂƌĞ ?ůĂďĞůůĞĚ “ƉĐ ? ?ĂĐĐŽƵŶt for large proportions also.  
 
 
Figure 5 Total cost across settings by chronic condition (1 of 3) 
 
Figure 6 Total cost across settings by chronic condition (2 of 3) 
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Figure 7 Total cost across settings by chronic condition (3 of 3) 
 
 
 
Average costs by condition and setting 
In Figure 8 to Figure 10 we provide a breakdown across settings of the average cost for people with 
particular conditions. Note that the scale of each of these three graphs differs. 
 
x The conditions are ordered from the highest average cost - Occupational Pulmonary 
Disease (£14,142) - in Figure 8 to the lowest  W Asthma (£1,337) - in Figure 10. 
x For most conditions, inpatient and day case costs account for the largest proportion of 
average costs, as indicated by the red section of each bar.  
x Some conditions stand out as having large proportions of costs incurred in other settings. 
So, for example, social care costs (light blue section) account for relatively large 
proportions of the average cost for people with dementia, epilepsy and burns. 
x Mental health care costs account for a substantial proportion of the average cost for those 
with dementia, alcohol dependence, poisonings and effects of drugs, burns, environmental 
trauma and eating disorders. 
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Figure 8 Average costs by setting, across chronic conditions (1 of 3) 
 
 
 
Figure 9 Average costs by setting, across chronic conditions (2 of 3) 
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Figure 10 Average costs by setting, across chronic conditions (3 of 3) 
 
 
  
£0
£500
£1,000
£1,500
£2,000
£2,500
£3,000
A
v
e
ra
g
e
 c
o
st
 p
e
r 
p
a
ti
e
n
t(
£
)
Average costs per setting across ETGs
cc
sc
cm
mh
ae
op
ip
pc
16  CHE Research Paper 96 
658 597 694 626 631 616 650 
859 
1053 
1307 
1839 
2408 
3319 
5264 
£0
£1,000
£2,000
£3,000
£4,000
£5,000
£6,000
20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
A
v
e
ra
g
e
 c
o
st
 p
e
r 
p
a
ti
e
n
t 
(£
) 
Age bands in years 
Average costs by age group 
6. Explaining variations in cost 
Age is often considered an important predictor of costs, and indeed it is important. This is illustrated 
in Figure 11 which plots average costs by 5-year age bands for the South Somerset population. 
Average costs of around £650 per year vary little across age bands 20-24 through to 55-59, after 
which costs increase ever more steeply, reaching almost £5,000 a year for those over 85.  
 
 
Figure 11 Average costs by age band 
 
But age alone does not explain costs: there are other factors that need to be considered. Risk-
adjustment involves determining predictors of cost, some of which may be correlated. An example 
of correlated cost predictors is age and the number of conditions: the older that people are, the 
more the conditions they have, and the higher their expected costs.  There is a clear age gradient, 
with older people having more conditions. This is illustrated in Figure 12 which plots the number of 
chronic conditions by 5-year age bands for the South Somerset population. At the extremes, fewer 
than 20% of those aged 0-4 have 1 or more conditions while almost 50% of those aged 85+ have 
three or more chronic conditions. 
 
This raises the question of what drives higher costs  W is age or the number of conditions more 
important? We can use regression analysis to disentangle the relative contributions that age and the 
number of conditions have on costs, as well as exploring the impact of other potential cost 
predictors. We have performed a simple examination of the data for the entire population, the 
results of which are summarised in Table 4: 
 
Table 4 Summary of regression results 
Regression 
variables 
Age 
Number of 
conditions 
Age, 
Number of 
conditions 
Number of 
chronic conditions 
Age, 
Number of chronic 
conditions 
Variation 
explained 
3.36% 19.80% 19.80% 10.48% 10.66% 
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Figure 12 Relationship between age and the number of chronic conditions (ETGs) 
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x In contrast, the number of conditions (whether chronic or not) has greater explanatory 
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x A regression model which considers both age and the number of conditions in combination 
is able to explain the same amount of the variation in costs (the increase in explanatory 
power amounts to less than 0.01%). The very small increase in explanatory power suggests 
that it is the number of conditions, not age, that is most important in explaining variation 
in costs among the South Somerset population. 
x If we consider only the number of chronic conditions, these explain 10.48% of the variation 
in costs among individuals. Again, adding age as an additional variable adds little 
explanatory power, R
2
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7. Analysis of costs for those with diabetes 
Overview 
5,625 people over 18 are recorded as having diabetes in South Somerset, their total costs amounting 
to £17m. A breakdown of these costs by setting is provided in Table 5 and the pie chart in Figure 13. 
Inpatient care accounts for the largest proportion of costs (35%), followed by social care (19%) and 
prescribing (14%). 
 
Table 5 Total cost by setting 
GP practice (GP) £1,023,765 
Prescribing (Rx) £2,406,176 
Inpatient (IP) £5,955,165 
Outpatient (OP) £1,429,150 
AE  £215,722 
Mental health (MH) £1,036,952 
Community care (CM) £764,655 
Social care (SC) £3,284,967 
Continuing care (CC) £1,040,761 
Total cost £17,157,314 
 
 
 
Figure 13 Cost by setting 
 
In Figure 14 we summarise average cost by the number of co-morbidities for those with a diagnosis 
of diabetes. For those (n=779) with a sole diagnosis of diabetes, costs are around £1,000 on average. 
As people are recorded as having more diagnoses, average costs increase progressively. 
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Figure 14 Cost by number of co-morbidities 
 
 
 
Figure 15 Top 15 most frequent co-morbidities for those with diabetes 
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Co-morbidity patterns 
In Figure 15 we show the most common co-morbidities for those with a diagnosis of diabetes.
1
 The 
following patterns are evident: 
x Hypertension is far and away the most common co-morbidity for people with diabetes, a 
reflection of this being the most common diagnosis in the population as a whole.  
x Of the 890 people with diabetes and three other co-morbidities, 27% have a diagnosis of 
coronary artery disease (CAD). This proportion rises to 40% when considering the 532 
people with diabetes and four other co-morbidities. 
 
Costs and co-morbidities 
The spider diagrams below (Figure 16 to Figure 19) show average costs for all those with a diagnosis 
of diabetes and any other condition (red line) and the specific co-morbidity (blue line) 
 
x Consider Figure 16. The average cost for the 1,544 people with diabetes and one other co-
morbidity amounts to £1,363. 
x The 854 people with diabetes and hypertension have below average costs of £1,091. 
x The 51 people with diabetes and cancer have above average costs of £3,589. 
x Similarly, those with diabetes and renal failure (n=5) and heart failure (n=7) have above 
average costs. 
x For those with 2+ comorbities (Figure 17), those with renal failure (n=23) have average 
costs of around £6,000. 
x For those with diabetes and 3 or 4+ conditions (Figure 18, Figure 19), costs appear driven 
as much by the number of conditions as the type: there is little difference between the red 
and blue lines. 
x The exceptions are renal failure, skin infections, skin trauma and stroke, the costs for 
people with these combinations being above average. 
 
                                                          
1
 All spider diagrams are drawn from the whole population, not just those over 18. 
EǀŝĚĞŶĐĞĨƌŽŵ^ŽƵƚŚ^ŽŵĞƌƐĞƚ ?Ɛ^ǇŵƉŚŽŶǇWƌŽũĞĐƚ  21 
 
 
 
Figure 16 Diabetes plus 1 co-morbidity 
 
 
 
Figure 17 Diabetes plus 2 co-morbidities 
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Figure 18 Diabetes plus 3 co-morbidities 
 
 
Figure 19 Diabetes plus 4 or more co-morbidities 
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Regression analyses 
In Table 6 we summarise the results of regression analyses of costs incurred in each setting. The 
following points are of note: 
 
x Virtually no-one with diabetes has zero primary care or prescribing costs. 
x In contrast, substantial proportions incur no costs in the other settings. This is particularly 
evident for mental health, community care, and continuing care costs. 
x We are able to explain more than 20% of the variation in primary care and prescribing 
costs. The inclusion of the variables indicating the broad type of co-morbidity adds little 
explanatory power. 
x 30% of those with diabetes are recorded as having positive inpatient costs but we are able 
to explain only 15% of the variation in these costs. The co-morbidity variables help improve 
explanatory power by 3%.  
x Very few people with diabetes incur mental health or continuing care costs, but for these 
people explanatory power is high at 24% and 45% respectively. The inclusion of the co-
morbidity variables improves explanatory power considerably. 
x The models are poor at explaining variation in social care costs. 
x We are able to explain 34% of the variation in total costs by taking account only of age, 
gender, deprivation, the number of co-morbidities and whether patients died or moved 
elsewhere. Explanatory power increases to 36% if the set of co-morbidity variables is 
included. 
 
Table 6 Summary of explanatory power from regression analyses: diabetes 
Setting % with zero costs Model 
Explanatory power 
Limited Full 
Primary care 0.55 Log 20% 21% 
Prescribing  1.01 Log 21% 22% 
Inpatient 69.81 Two-part 12% 15% 
Outpatient 44.66 Two-part 7% 9% 
A&E 78.93 Two-part 19% 21% 
Mental health 96.68 Two-part 14% 24% 
Community care 97.03 Two-part 39% 45% 
Social care 89.64 Two-part 2% 6% 
Continuing care 97.85 Two-part 21% 42% 
Total 0.18 Log 34% 36% 
 
Table 7 summarises the influence on total costs of the various characteristics of individuals.  A 
positive coefficient indicates that the characteristic in question increases costs and the stars indicate 
the significance level of the characteristic.  
 
x Deprivation status and the presence of mental health problems or arthritis are not 
significant influences on the costs of people with diabetes. 
x Costs are higher for older people, women, those with more co-morbidities and those who 
died.  
x Costs are higher if people are diagnosed with one of the sets of conditions (with the 
exceptions of mental health problems or arthritis). 
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Table 7 Influence of characteristics in explaining total costs for those with diabetes 
Variable Estimate 
Age 0.006*** 
Male -0.100*** 
Deprivation 0.003 
Number of co-morbidities 0.263*** 
Died 1.188*** 
Moved elsewhere -0.095 
Dementia 0.937*** 
Mental health (exc dementia) 0.069 
Cancer 0.176*** 
Cardio-vascular disease 0.207*** 
Stroke 0.163*** 
Obesity 0.562*** 
Respiratory problems 0.138** 
Gastric problems 0.134* 
Trauma/burns/fractures 0.382*** 
Arthritis -0.030 
Renal problems 0.569*** 
Significance: * p<0.1; ** p<0.5; *** p<0.01 
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8. Analysis of costs for those with dementia 
Overview 
Although people with dementia account for only 0.92% of the South Somerset population, the total 
costs for the 1,062 people recorded as having dementia amounts to £13m (Table 8 and Figure 20) 
 
Table 8 Total cost by setting 
GP practice (GP) £174,461 
Prescribing (Rx) £472,807 
Inpatient (IP) £1,873,156 
Outpatient (OP) £144,990 
AE  £81,571 
Mental health (MH) £1,524,991 
Community care (CM) £809,701 
Social care (SC) £4,176,938 
Continuing care (CC) £3,818,728 
Total cost £13,077,343 
 
 
Figure 20 Cost by setting 
 
For people with dementia there is no obvious pattern between the number of conditions and 
average costs (Figure 21).  This is partly because dementia itself is the largest cost driver: the 
average cost for people with dementia alone is more than £12,000. Additional conditions are likely 
to be of lower cost. It is also due to the high proportions of total costs accounted for by the costs of 
continuing care and social care, which do not appear to be driven by multi-morbidity.  
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Figure 21 Cost by number of co-morbidities 
 
Co-morbidity patterns 
In Figure 22 we show the most common co-morbidities for those with a diagnosis of dementia. 
 
 
Figure 22 Top 15 most frequent co-morbidities for those with diabetes 
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x For those with a single additional co-morbidity, this tends to hypertension, which is present 
for 35% of such people. 
x This tendency for hypertension to be present is evident also for those with more co-
morbidities. Indeed, for 80% of people with dementia and four or more co-morbidities, 
hypertension is one of the co-morbidities. 
x Among those with four co-morbidities, there is a wide variety of what these other co-
morbidities are. 41% have a diagnosis of coronary artery disease, 35% stroke, and 30% 
have cancer or diabetes. 
 
Costs and co-morbidities 
x As Figure 23 shows, the 20 people with dementia who suffered a fracture have costs 
substantially above the average for those with one or two additional diagnoses.  
 
x Average costs for those with dementia and 4+ conditions (Figure 25) appear driven as 
much by the number of conditions as the type: there is little difference between the red 
and blue lines. 
 
 
 
Figure 23 Dementia plus 1 or 2 co-morbidities 
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Figure 24 Dementia plus 3 co-morbidities 
 
 
Figure 25 Dementia plus 4 or more co-morbidities 
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Regression analyses 
Table 9 summarises the results of regression analyses of costs for those with dementia by setting 
and in total. The following points are of note: 
 
x Very few people have zero primary care or prescribing costs and only 0.5% of people with 
dementia are recorded as having no costs at all.  
x Even so, quite large proportions of people (>50%) incur no costs in the other settings. 
x We are able to explain 20% of the variation in primary care and 16% of variation in 
prescribing costs. The inclusion of co-morbidity variables indicating the broad type of co-
morbidity adds little explanatory power. 
x Around 44% of those with dementia were treated as inpatients. We are able to explain 
16% of the variation in inpatient costs. Here the co-morbidity variables help improve 
explanatory power by 6%.  
x 18% of people with dementia had continuing care costs, but for these people explanatory 
power is reasonably good at 27%. The inclusion of the co-morbidity variables improves 
explanatory power considerably. 
x The models are poor at explaining variation in the costs of mental health care (7%) and 
social care (4%). 
x We are able to explain 11% of the variation in total costs by taking account of age, gender, 
deprivation, the number of co-morbidities and whether patients died or moved elsewhere. 
Explanatory power increases to 15% if the set of co-morbidity variables is included. 
 
Table 9 Summary of explanatory power from regression analyses: dementia 
Setting % with zero costs Model 
Explanatory power 
Limited Full 
Primary care 1.13 Log 18% 20% 
Prescribing  2.17 Log 15% 16% 
Inpatient 56.31 Two-part 10% 16% 
Outpatient 57.34 Two-part 9% 13% 
A&E 62.24 Two-part 15% 20% 
Mental health 50.38 Two-part 3% 7% 
Community care 92.75 Two-part 6% 24% 
Social care 51.32 Two-part 3% 4% 
Continuing care 82.02 Two-part 18% 27% 
Total 0.47 Log 11% 15% 
 
Table 10 summarises the influence on total costs of the various characteristics of individuals.  
 
x Age and gender are not significant influences on the costs of people with dementia. 
x Costs are higher for those from more deprived areas, those with more co-morbidities and 
those who died.  
x Costs are higher if people are diagnosed with Trauma/burns/fractures and Renal problems 
but not for the other variables (with the exceptions of Stroke and Respiratory problems at 
lower significance levels). 
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Table 10 Influence of characteristics in explaining total costs for those with dementia 
Variable Estimate 
Age 0.01 
Male -0.10 
Deprivation 0.02*** 
Number of co-morbidities 0.14*** 
Died 0.67*** 
Moved elsewhere 0.07 
Diabetes 0.08 
Mental health (exc dementia) 0.23 
Cancer -0.18 
Cardio-vascular disease -0.09 
Stroke 0.23* 
Obesity 1.37 
Respiratory problems 0.30* 
Gastric problems 0.00 
Trauma/burns/fractures 0.61*** 
Arthritis -0.59 
Renal problems 0.54** 
Significance: * p<0.1; ** p<0.5; *** p<0.01 
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9. Analysis of costs for those with diabetes and dementia 
Overview 
6,521 people are recorded as having either diabetes or dementia. There is little overlap between 
these groups: only 166 (2%) people are identified as having both conditions (Figure 27). The total 
cost of care for this combined group amounts to £28m (Table 11 and Figure 26). 
 
Table 11 Total cost by setting 
GP practice (GP) £1,163,285 
Prescribing (Rx) £2,778,463 
Inpatient (IP) £7,456,346 
Outpatient (OP) £1,543,905 
AE  £281,422 
Mental health (MH) £2,288,199 
Community care (CM) £1,504,421 
Social care (SC) £6,651,990 
Continuing care (CC) £4,401,048 
Total cost £28,069,078 
 
 
 
Figure 26 Costs by setting 
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Figure 27 Composition of those with diabetes and dementia 
 
Regression analyses 
Table 12 summarises the results of regression analyses of costs incurred in each setting. The 
following points are of note: 
 
x Very few people have zero primary care or prescribing costs and only 0.2% of people are 
recorded as having no costs at all.  
x Quite large proportions of people incur no costs in the other settings. 
x We are able to explain 21% of the variation in primary care and 20% of variation in 
prescribing costs.  
x Around 32% of those with diabetes or dementia were treated as inpatients. We are able to 
explain 16% of the variation in inpatient costs.  
x 4% of people with diabetes or dementia had continuing care costs, but for these people 
explanatory power is reasonably good at 33%. The inclusion of the co-morbidity variables 
improves explanatory power by 8%. 
x The models are poor at explaining variation in social care costs. 
x We are able to explain 36% of the variation in total costs by taking account only of the 
limited set of variables. Explanatory power increases to 38% if the set of co-morbidity 
variables is included. 
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Table 12 Summary of explanatory power from regression analyses: diabetes & dementia 
Setting % with zero costs Model 
Explanatory power 
Limited Full 
Primary care 0.64 Log 20% 21% 
Prescribing  1.21 Log 20% 20% 
Inpatient 68.29 Two-part 12% 16% 
Outpatient 46.73 Two-part 8% 10% 
A&E 78.64 Two-part 18% 21% 
Mental health 90.17 Two-part 11% 13% 
Community care 96.46 Two-part 41% 46% 
Social care 84.62 Two-part 7% 8% 
Continuing care 95.72 Two-part 25% 33% 
Total 0.23 Log 36% 38% 
 
Table 13 summarises the influence on total costs of the various characteristics of individuals. 
x Costs are lower for males. 
x Costs are higher for older people, women, those from more deprived areas, those with 
more co-morbidities, and those who died during the year.  
x Costs are higher if people are diagnosed with all groups of conditions except gastric 
problems and arthritis. 
 
Table 13 Influence of characteristics in explaining total costs for those with diabetes and dementia 
Variable Estimate 
Age 0.008*** 
Male -0.098*** 
Deprivation 0.005*** 
Number of co-morbidities 0.247*** 
Died 1.051*** 
Moved elsewhere -0.045 
Dementia, no diabetes 1.050*** 
Dementia and diabetes 0.959*** 
Mental health (excluding dementia) 0.085* 
Cancer 0.114** 
Cardio-vascular disease 0.155*** 
Stroke 0.140*** 
Obesity 0.570*** 
Respiratory problems 0.157*** 
Gastric problems 0.097 
Trauma/burns/fractures 0.425*** 
Arthritis -0.121 
Renal problems 0.569*** 
Significance: * p<0.1; ** p<0.5; *** p<0.01 
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10. Conclusions  
^ŽƵƚŚ^ŽŵĞƌƐĞƚ ?Ɛ^ǇŵƉŚŽŶǇWƌŽũĞĐƚŝƐĚĞƐŝŐŶĞĚƚŽĞƐƚĂďůŝƐŚŐƌĞĂƚĞƌĐŽůůĂďŽƌĂƚŝŽŶďĞƚǁĞĞŶƉƌŝŵĂƌǇ ?
community, mental health, acute and social care, particularly for people with complex conditions. 
The Project recognises that financial arrangements need to be revised so as to support organisations 
to work collaboratively around the needs of patients (Department of Health, 2012). 
 
To support this ambition, the Symphony Project has built a large dataset comprising information 
about each anonymised individual in the South Somerset population. The dataset has three key 
features: (i) it links acute, primary care, community, mental health and social care data; (ii) costs are 
assigned to each individual according to the type of care they have received in each setting; and (iii) 
demographic characteristics are available for each individual, including age, gender, socio-economic 
measures, and indicators of morbidity.  
 
We define a set of chronic conditions allowing us to examine the multi-morbidity profile of each 
individual. This allows us to describe the frequency of occurrence of each chronic condition in the 
population; the combinations of each condition with other co-morbidites; the utilisation of services 
across different settings; and the costs of care.  
 
As well as looking at the population as a whole, we perform sub-group analyses for people with 
specific conditions, namely diabetes, dementia, hypertension, asthma, fractures, coronary artery 
disease, cancer, chronic obstructive pulmonary disease, stroke and mental health (other than 
dementia). 
 
We analyse why costs vary from one person to another by applying multivariate regression models 
ƚŽ ĂŶĂůǇƐĞ ĞĂĐŚ ƉĞƌƐŽŶ ?Ɛ ƚŽƚĂů ĐŽƐƚƐ ĂŶĚ ĐŽƐƚƐ ŝŶĐƵƌƌĞĚ ŝŶĞĂĐŚ ƐĞƚƚŝŶŐ ? tŚŝůĞ ĐŽƐƚƐ ĂƌĞ ƉŽƐŝƚŝǀĞůǇ
associated with age, we find that multi-morbidity is much more important in explaining variations in 
costs across individuals. In fact, age adds little explanatory power once we have accounted for the 
number of conditions in analysing costs.  
 
This work forms a basis for identifying groups that would most benefit from improved integrated 
care, which might be facilitated by integrated financial arrangements and better pathway 
management. The more co-morbidities that a person has, the more likely they are to require care 
across diverse settings, and the higher their costs. Our analysis identifies those groups of the 
population which are the highest users of services by activity and cost and provides baseline 
information to allow budgetary arrangements to be developed for these targeted groups. 
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Appendix: Analysis of selected conditions 
We explore the multi-morbidity profiles and cost data for each condition across settings and 
according to the number of conditions people have. Figures 28  W 43 provide examples for those 
people recorded as having hypertension, asthma, fractures, coronary artery disease, cancer, chronic 
obstructive pulmonary disease, stroke and mental health (other than dementia).  
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Hypertension 
x Hypertension is the most common diagnosis, recorded for 17,777 of the South Somerset 
population. 
x The total cost of care received by these people amounts to £45m, reflecting both the 
number of people with this diagnosis and the common combination of hypertension with 
other co-morbidities. 
x Hypertension alone is not a big driver of costs, average costs for people with only this 
diagnosis amounting to £667. 
x Diverse diagnoses are recorded alongside hypertension, notably diabetes, cancer, 
hyperthyroidism, CAD, asthma and stroke. 
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Figure 28 Average costs by setting and number of conditions, hypertension 
 
 
Figure 29 Top 15 most frequent co-morbidities for those with hypertension 
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Asthma 
x Asthma is the second most common diagnosis (after hypertension) in the South Somerset 
population (n=12,769). The total cost of care for these patients amounts to £17m. 
x Alone asthma is not a costly condition to manage, the average cost amounting to around £400.  
x As asthma is combined with other (invariably more costly) conditions, the average costs 
increase for people who are recorded as having asthma. This is due to the management of 
these other conditions, rather than asthma itself. 
x No specific co-morbidity stands out for those with a single additional co-morbidity. 
x As more co-morbidities are recorded, the likelihood is that one of these will be 
hypertension or anxiety (largely reflecting their presence in the population). 
x For those with multiple co-morbidities (4+), there is a wide range of combinations of what 
these might be. 
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Figure 30 Average costs by setting and number of conditions, Asthma 
 
 
Figure 31 Top 15 most frequent co-morbidities for those with asthma 
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Fractures 
x Fracture is recorded for 1,546 people, the total cost of care for these patients amounting 
to £7.2m. 
x 511 people are recorded as having a fracture only, the average cost amounting to £1,700.  
x As more conditions are recorded, average costs increase. 
x Most costs are incurred in the inpatient setting. 
x For those with a single additional co-morbidity, this tends to be asthma (20%) or 
hypertension (15%). 
x This tendency for asthma or hypertension to be present is evident also for with those with 
two or three additional co-morbidities. 
x For people with four or more co-morbidities, hypertension is invariably present (>70%), but 
there is a wide variety of other co-morbidities. 
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Figure 32 Average costs by setting and number of conditions, fracture 
 
 
 
Figure 33 Top 15 most frequent co-morbidities for those with fractures 
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Coronary Artery Disease 
 
x 4,695 people have coronary artery disease, the total costs of their care amounting to 
£18.3m. 
x 695 people have this sole diagnosis, their costs amounting to around £1,300 on average. 
x Inpatient costs account for the highest proportion of costs, with social care costs increasing 
in importance as more co-morbidities are recorded. 
x Hypertension is the most common co-morbidity for people with CAD, followed by diabetes 
and cancer. 
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Figure 34 Average costs by setting and number of conditions, coronary artery disease 
 
 
 
Figure 35 Top 15 most frequent co-morbidities for those with CAD 
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Cancer 
 
x There are 5,932 people with a cancer diagnosis, the total costs of their care amounting to 
£19m. 
x 1,069 people have this sole diagnosis, their costs amounting to around £1,300 on average. 
x Inpatient costs account for the highest proportion of costs, with social, community and 
primary care costs increasing progressively in importance as more co-morbidities are 
recorded. 
x Breast disorders and hypertension are the most common co-morbidities. 
  
EǀŝĚĞŶĐĞĨƌŽŵ^ŽƵƚŚ^ŽŵĞƌƐĞƚ ?Ɛ^ǇŵƉŚŽŶǇWƌŽũĞĐƚ  45 
 
 
 
Figure 36 Average costs by setting and number of conditions, cancer 
 
 
Figure 37 Top 15 most frequent co-morbidities for those with Cancer 
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Chronic obstructive pulmonary disease 
 
x 1,989 people have a diagnosis of COPD, the total costs of their care amounting to £7.6m. 
x Only 202 (10%) have this sole diagnosis, their costs amounting to around £1,000 on 
average and for whom primary care costs account for the greatest proportion. 
x The more diagnoses recorded, the greater the proportion of costs incurred in inpatient and 
social care settings. 
x Asthma and hypertension are the most common co-morbidities. 
x There is a wide diversity of co-morbidities for those with 4+ co-morbidities 
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Figure 38 Average costs by setting and number of conditions, COPD 
 
 
 
Figure 39 Top 15 most frequent co-morbidities for those with COPD 
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Stroke 
 
x 2,665 people are recorded as having suffered a stroke, the total cost of their care 
amounting to £14m. 
x Only 10% of these people have stroke as a sole diagnosis, their average costs amounting to 
£2,100. 
x Care is provided across various settings, with social care accounting for a high proportion 
of costs. 
x As more diagnoses are recorded, costs in other settings increase, notably inpatient, 
community, primary and continuing care. 
x Hypertension is by far the most common additional diagnosis, irrespective of how many 
diagnoses are recorded. 
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Figure 40 Average costs by setting and number of conditions, Stroke 
 
 
 
Figure 41 Top 15 most frequent co-morbidities for those with Stroke 
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Mental health (other than dementia) 
 
x 1,294 people diagnosed with Mental Health problems (other than dementia), their total 
costs amounting to £7.1m. 
x Costs are high, amounting to almost £3,700 for those for whom Mental health is the sole 
diagnosis. 
x Costs are incurred across diverse settings, increasingly so as people have more co-
morbidities. 
x For those with a single additional co-morbidity, this tends to be anxiety (40%), followed by 
eating disorders (15%). 
x As more co-morbidities are recorded the likelihood of having a diagnosis of anxiety 
increases markedly but alcohol dependence, asthma and hypertension also become 
common. 
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Figure 42 Average costs by setting and number of conditions, mental health 
 
 
 
Figure 43 Top 15 most frequent co-morbidities for those with Mental health condition 
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